Post Profile






Nivolumab maintains function, reduces symptoms in treatment of relapsed metastatic head and neck cancer

Nivolumab maintains function and reduces symptoms in treatment of relapsed metastatic head and neck cancer, according to results from the CheckMate 141 trial.
read more

share

Related Posts


Ceritinib provides longer progression-free survival than chemotherapy in phase III trial of ALK rearranged lung cancer treatment

Diseases & Conditions / Cancer : ScienceDaily: Cancer

Ceritinib provides longer progression-free survival than chemotherapy in crizotinib-pre-treated patients with non-small-cell lung cancer harbouring an ALK rearrangement, according to results of the phase III ASCEND-5 study.

Pembrolizumab new option for first line treatment of patients with advanced lung cancer and high PD-L1 expression

Diseases & Conditions / Cancer : ScienceDaily: Cancer

Pembrolizumab is set to become a new option for first line treatment of patients with advanced lung cancer and high PD-L1 expression, according to the results of the phase III KEYNOTE-024 trial.

Nintedanib improves progression-free survival but not overall survival in phase III trial of metastatic colorectal cancer

Diseases & Conditions / Cancer : ScienceDaily: Cancer

Nintedanib improves progression-free survival but not overall survival in patients with metastatic colorectal cancer who are not responding to standard therapies, according to results of the phase III LUME-colon 1 trial.

Immunotherapy drug a 'gamechanger' for head and neck cancer

Health : The Guardian: Health

Nivolumab found to extend lives of relapsed patients who had run out of therapy options An immunotherapy drug hailed as a potential “gamechanger” in the treatment of cancer could soon offer new hope to patients with currently untrea...

Nivolumab reduces symptoms in relapsed metastatic head and neck cancer

Health : EurekAlert: Health

(European Society for Medical Oncology) Nivolumab maintains function and reduces symptoms in treatment of relapsed metastatic head and neck cancer, according to results from the CheckMate 141 trial presented at the ESMO 2016 Congres...

Comments


Copyright © 2016 Regator, LLC